Health Canada is increasing its oversight of Grifols, a Spanish-based company operating 16 paid plasma collection centers across Canada, including two in Toronto. This decision follows multiple failed inspections and the recent deaths of two plasma donors in Winnipeg. The federal health regulator found "recurring, systemic deficiencies" during inspections, prompting the imposition of new terms and conditions on all Grifols' Canadian locations.
A recent inspection of Grifols' Canadian head office in Oakville, Ontario, revealed the company wasn't accurately assessing donor suitability, thoroughly investigating errors, or employing enough qualified staff. Health Canada also found that operating procedures weren't always followed, and individuals were allowed to donate plasma even when it appeared "the safety of blood could be affected". The agency is requiring Grifols to reduce appointment numbers, reassess staffing levels and training, and enhance quality control measures. These measures will remain in place until Grifols demonstrates consistent compliance with regulations.
The Canadian Health Coalition and other health advocates have criticized Health Canada's response, arguing the measures don't go far enough. They are calling for a ban on for-profit plasma collection and greater scrutiny of the industry. Currently, provinces like British Columbia, Quebec, and Ontario prohibit paid plasma donation, while others, like Alberta, permit it to increase domestic supply. Concerns persist about the potential for paid donation to exploit vulnerable populations and compromise the safety of the blood supply.
Plasma, the protein-rich liquid in blood, is used to create medications for various conditions, including immune deficiencies and liver diseases. Canadian Blood Services has an agreement with Grifols to collect plasma, but faces increasing pressure to end the partnership. The debate continues regarding the ethical and safety implications of paid versus voluntary plasma donation in Canada.
